CA-OBSIDIAN-SECURITY
We’re thrilled to share that Obsidian Security has been named a Strong Performer while receiving the highest scores possible across five criteria in The Forrester Wave™: SaaS Security Posture Management, Q4 2023 – the first Forrester Wave(™) report to be released in the SaaS Security and Posture Management (SSPM) category.
Forrester gave the Obsidian Posture Management module the highest scores possible in the configuration drift detection and SaaS app configuration templates criteria. Additionally, the Obsidian Integration Risk Management module received the highest possible score in the connected apps criterion. Forrester also gave Obsidian the highest score possible in the IAM administration criterion supported by Obsidian Advanced Threat Mitigation module. The Forrester report recognized Obsidian as a vendor providing “a single, modular platform” for SaaS Security and Posture Management.
The Obsidian Advanced Threat Mitigation module covers authentication monitoring and remediation, which includes unusual login, impossible travel, no multifactor authentication, password expiration, and session keepalive management.
"We are thrilled and humbled to receive recognition from Forrester. To us, this acknowledgment as a Strong Performer is for our commitment to building the category-leading solution supported by a single platform. Our underlying architecture, built on a graph database, allows us to innovate rapidly and have deep context on what matters to our customers. We are grateful to our customers and partners who push us to be better every day, as we believe is evidenced by Obsidian receiving the highest possible score in the adoption criterion," said Hasan Imam, CEO, Obsidian Security.
Obsidian raised Series C of $90 million in 2022 from Menlo Ventures, Institutional Venture Partners and Norwest Venture Partners with participation from Greylock Partners, Wing Ventures and Google Ventures. Obsidian customers include Fortune 500 banks, asset managers, insurers, telcos, high tech, healthcare providers, media companies. As a global company, Obsidian currently serves over 175 customers with offices across North America, Europe, Middle East, and Australia, with plans to support more countries in Asia Pacific in 2024.
With this recognition, Obsidian Security will continue to set the standard for SSPM. With a focus on tangible capabilities and robust security measures, Obsidian remains a trusted partner for organizations seeking top-tier SSPM solutions.
About Obsidian Security
Obsidian Security is the premier security solution designed to drastically reduce the attack surface area of SaaS applications by 80% on average. With contextual user activity data, configuration posture, and a rich understanding of 3rd party integrations in SaaS, the Obsidian platform reduces incident response times by 10x and streamlines compliance with internal policies and industry regulations. Notable Fortune 500 companies trust Obsidian Security to secure SaaS applications, such as Salesforce, GitHub, ServiceNow, Workday, and Atlassian. Headquartered in Southern California, Obsidian Security is a privately held company backed by Menlo Ventures, Norwest Venture Partners, Greylock Partners, IVP, GV, and Wing. For more information, visit www.obsidiansecurity.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231211979474/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
